← Back to Search

Brachytherapy

Radiation Therapies for Prostate Cancer

N/A
Waitlist Available
Led By Peter Chung, MB ChB
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether or not delivering radiation to a specific area in the prostate, as seen on MRI, at a higher than normal dose is safe and effective.

Who is the study for?
This trial is for men with prostate cancer who have a life expectancy of over 10 years and are fit (ECOG status 0 or 1). They must have visible tumors on MRI, be at least 18 years old, and not exceed a weight of 136kg due to scanner limits. Men with pacemakers or certain metal implants cannot participate. Those currently on hormone therapy or with other cancers in the last five years are also excluded.
What is being tested?
The study tests high-dose radiation targeting tumor nodules within the prostate gland using MRI guidance. It aims to see if delivering higher doses directly to the tumor can prevent cancer from remaining or returning after standard treatments like surgery, EBRT, or brachytherapy.
What are the potential side effects?
While specific side effects aren't listed here, high-dose radiation may cause urinary issues, bowel problems such as diarrhea and discomfort, fatigue, sexual dysfunction, and skin irritation around the treated area.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Prior Radiation Treatment (Control Cohort)Experimental Treatment1 Intervention
Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
Group II: Active Radiation Treatment (Cohort 2)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,519 Previous Clinical Trials
503,087 Total Patients Enrolled
65 Trials studying Prostate Cancer
15,507 Patients Enrolled for Prostate Cancer
Princess Margaret Hospital, CanadaOTHER
119 Previous Clinical Trials
39,019 Total Patients Enrolled
8 Trials studying Prostate Cancer
9,455 Patients Enrolled for Prostate Cancer
Peter Chung, MB ChBPrincipal InvestigatorUniversity Health Network, The Princess Margaret
3 Previous Clinical Trials
512 Total Patients Enrolled

Media Library

High-Dose Rate (HDR) Radiotherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01802242 — N/A
Prostate Cancer Research Study Groups: Active Radiation Treatment (Cohort 2), Prior Radiation Treatment (Control Cohort)
Prostate Cancer Clinical Trial 2023: High-Dose Rate (HDR) Radiotherapy Highlights & Side Effects. Trial Name: NCT01802242 — N/A
High-Dose Rate (HDR) Radiotherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01802242 — N/A
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top